As understanding of the human microbiome improves, novel therapeutic targets to improve human health with microbial therapeutics will continue to expand. We outline key considerations of balancing risks and benefits, optimizing access, returning key results to research participants, and potential conflicts of interest.
Read the full paper at: https://www.ncbi.nlm.nih.gov/pubmed/29039256